Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 1.00 |
| ▸ | RPA1 | P27694 | 5/20 | 0.89 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.89 |
| ▸ | PPP1CA | P62136 | 3/20 | 0.84 |
| ▸ | MARS1 | P56192 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 3/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | ATM | Q13315 | 1/20 | 0.78 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.74 |
| ▸ | BCL2 | P10415 | 2/20 | 0.64 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1514681 | 0.94 | L3MBTL1 (0.89) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL4488017 | 0.94 | RPA1 (1.00) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL1514559 | 0.92 | PPP1CA (1.00) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL695352 | 0.89 | RPA1 (1.00) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL116301 | 0.88 | MARS1 (1.00) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL4493013 | 0.87 | KMT2A (1.00) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL1110855 | 0.87 | PPP1CA (0.87) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| Hydrochloric Acid SCHEMBL8742176 | 0.86 | SMN1; SMN2 (0.97) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL27714729 | 0.85 | KMT2A (0.89) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 | |
| SCHEMBL1765047 | 0.85 | PPP1CA (0.78) | L3MBTL1RPA1SMN1; SMN2PPP1CAMARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | claimed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | claimed |
| CN-102659774-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE | 2012-09-12 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| CN-101282972-A | Piperidine and piperazine derivatives as P2X3 antagonists | HOFFMANN LA ROCHE (CH) | 2008-10-08 | — | — | CN | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
| EP-1237849-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001032604-A1 | ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | UNIVERSITY COLLEGE LONDON (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | L3MBTL1 861/4885RPA1 3427/4885SMN1; SMN2 3624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.